Shopping Cart 0
Cart Subtotal
USD 0

Pharma Mar SA (PHM) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750

Details

Summary

Pharma Mar SA (Pharma Mar) is a biopharmaceutical company that discovers, develops and markets marine-derived drugs to treat cancer. The company's marketed product Yondelis (trabectedin), a novel, multimodal, synthetically produced antitumor agent, is indicated for the treatment of advanced or metastatic soft tissue sarcoma and relapsed ovarian cancer. Pharma Mar's developmental pipeline includes Aplidin (plitidepsin) for multiple myeloma and T-cell lymphoma; PM1183 (lurbinectedin) for ovarian cancer; and PM184 for advanced breast cancer and solid tumors. It also develops RNAi candidates for the treatment of retina diseases. The company has subsidiaries in Germany, Italy, France, Switzerland, the UK, Belgium and the US. Pharma Mar is headquartered in Madrid, Spain.

Pharma Mar SA (PHM)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Pharma Mar SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Pharma Mar SA, Medical Devices Deals, 2012 to YTD 2018 10

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Pharma Mar SA, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Pharma Mar Enters into Distribution Agreement with Impilo Pharma 12

Pharma Mar Enters into Agreement with Spanish National Cancer Research Centre 13

Merger 14

Zeltia Merges with Pharma Mar in Reverse Merger Transaction 14

Licensing Agreements 15

Pint Pharma International Enters into Licensing Agreement with Pharma Mar 15

Seattle Genetics Enters into Licensing Agreement with Pharma Mar 16

Pharma Mar Enters into Licensing Agreement with Megapharm 17

Pharma Mar to Enter into Licensing Agreement with Boryung Pharma 18

Boryung Pharm Enters into Licensing Agreement with Pharma Mar 19

Eczacibasi Enters into Licensing Agreement with Pharma Mar 20

Specialised Therapeutics Asia Enters into Licensing Agreement with Pharma Mar 21

Boryung Pharma Enters into Licensing Agreement with Pharma Mar 22

Specialised Therapeutics Enters into Licensing Agreement with Pharma Mar 23

Specialised Therapeutics Enters into Licensing Agreement with Pharma Mar 24

TTY Biopharm Enters into Licensing Agreement with PharmaMar 25

PharmaMar Enters into Licensing Agreement with Chugai Pharma for Aplidin 26

PharmaMar Enters into Licensing Agreement with GP Pharm for Politrate Leuprorelin 27

Equity Offering 28

Pharma Mar Plans to Raise Funds through Public Offering of ADS 28

Pharma Mar SA-Key Competitors 29

Pharma Mar SA-Key Employees 30

Pharma Mar SA-Locations And Subsidiaries 31

Head Office 31

Other Locations & Subsidiaries 31

Recent Developments 33

Financial Announcements 33

Oct 30, 2018: PharmaMar reports net profit of EUR5 million at the end of the third quarter of 2018 33

Jul 26, 2018: PharmaMar group obtained a net profit of EUR3 million in the first half of 2018 34

Apr 26, 2018: Pharmamar Group Reports First Quarter Financial Results 35

Feb 28, 2018: PharmaMar group announces 2017 earnings results 36

Oct 24, 2017: Pharma Mar group revenues totalled EUR140 million in the first nine months of the year 37

Jul 26, 2017: Pharma Mar group reports first half financial results 38

Apr 27, 2017: PharmaMar Group reports EUR45.5 million in revenues (+8%) 39

Feb 24, 2017: PharmaMar continues to execute commercially in 2016, adds new partner for pipeline asset, and sees pipeline progress 40

Corporate Communications 42

Oct 01, 2018: PharmaMar names Ali Zeaiter as new Director of Clinical Development 42

Government and Public Interest 43

Mar 29, 2017: The success of sarcoma treatment, seen by prestigious international oncologists 43

Product News 45

06/16/2017: PharmaMar Will Commercialize PM1183 With the Trade Name of Zepsyre 45

04/27/2017: PharmaMar demonstrates its progress in R&D in New York 46

04/04/2017: PharmaMar Presents New Data on Lurbinectedin at the AACR Congress 47

Clinical Trials 48

Sep 19, 2017: PharmaMar Starts Clinical Studies with a New Compound -PM14- in Patients with Solid Tumors 48

Jun 13, 2017: PharmaMar Announces Encouraging Results in Clinical Trials of Lurbinectedin in Endometrial and Breast Cancers 49

May 18, 2017: PharmaMar Announces new data on Lurbinectedin during ASCO 2017 50

Other Significant Developments 51

Jul 30, 2018: Immedica-a platform for pan-European niche specialty pharma launch, commercialization and distribution services 51

Jun 28, 2018: PharmaMar's 2017 Group Annual General Shareholder's' meeting 52

Jun 29, 2017: PharmaMar Group reviews 2016 at its annual general shareholders meeting 54

Appendix 55

Methodology 55

About GlobalData 55

Contact Us 55

Disclaimer 55


List Of Figure

List of Figures

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Pharma Mar SA, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Pharma Mar SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Pharma Mar SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Pharma Mar SA, Deals By Therapy Area, 2012 to YTD 2018 9

Pharma Mar SA, Medical Devices Deals, 2012 to YTD 2018 10

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Pharma Mar Enters into Distribution Agreement with Impilo Pharma 12

Pharma Mar Enters into Agreement with Spanish National Cancer Research Centre 13

Zeltia Merges with Pharma Mar in Reverse Merger Transaction 14

Pint Pharma International Enters into Licensing Agreement with Pharma Mar 15

Seattle Genetics Enters into Licensing Agreement with Pharma Mar 16

Pharma Mar Enters into Licensing Agreement with Megapharm 17

Pharma Mar to Enter into Licensing Agreement with Boryung Pharma 18

Boryung Pharm Enters into Licensing Agreement with Pharma Mar 19

Eczacibasi Enters into Licensing Agreement with Pharma Mar 20

Specialised Therapeutics Asia Enters into Licensing Agreement with Pharma Mar 21

Boryung Pharma Enters into Licensing Agreement with Pharma Mar 22

Specialised Therapeutics Enters into Licensing Agreement with Pharma Mar 23

Specialised Therapeutics Enters into Licensing Agreement with Pharma Mar 24

TTY Biopharm Enters into Licensing Agreement with PharmaMar 25

PharmaMar Enters into Licensing Agreement with Chugai Pharma for Aplidin 26

PharmaMar Enters into Licensing Agreement with GP Pharm for Politrate Leuprorelin 27

Pharma Mar Plans to Raise Funds through Public Offering of ADS 28

Pharma Mar SA, Key Competitors 29

Pharma Mar SA, Key Employees 30

Pharma Mar SA, Subsidiaries 31

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Pharma Mar SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Pharma Mar SA (Pharma Mar) is a biopharmaceutical company that discovers, develops and markets marine-derived drugs to treat cancer. The company's marketed product Yondelis (trabectedin), a novel, multimodal, synthetically produced antitumor agent, is indicated for the treatment of advanced or metastatic soft tissue sarcoma and relapsed ovarian cancer. Pharma Mar's developmental pipeline includes Aplidin (plitidepsin) for multiple myeloma and T-cell lymphoma; PM1183 (lurbinectedin) for ovarian cancer; and PM184 for advanced breast cancer and solid tumors. It also develops RNAi candidates for the treatment of retina diseases. The company has subsidiaries in Germany, Italy, France, Switzerland, the UK, Belgium and the US. Pharma Mar is headquartered in Madrid, Spain.

Pharma Mar SA (PHM)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Pharma Mar SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Pharma Mar SA, Medical Devices Deals, 2012 to YTD 2018 10

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Pharma Mar SA, Pharmaceuticals & Healthcare, Deal Details 12

Partnerships 12

Pharma Mar Enters into Distribution Agreement with Impilo Pharma 12

Pharma Mar Enters into Agreement with Spanish National Cancer Research Centre 13

Merger 14

Zeltia Merges with Pharma Mar in Reverse Merger Transaction 14

Licensing Agreements 15

Pint Pharma International Enters into Licensing Agreement with Pharma Mar 15

Seattle Genetics Enters into Licensing Agreement with Pharma Mar 16

Pharma Mar Enters into Licensing Agreement with Megapharm 17

Pharma Mar to Enter into Licensing Agreement with Boryung Pharma 18

Boryung Pharm Enters into Licensing Agreement with Pharma Mar 19

Eczacibasi Enters into Licensing Agreement with Pharma Mar 20

Specialised Therapeutics Asia Enters into Licensing Agreement with Pharma Mar 21

Boryung Pharma Enters into Licensing Agreement with Pharma Mar 22

Specialised Therapeutics Enters into Licensing Agreement with Pharma Mar 23

Specialised Therapeutics Enters into Licensing Agreement with Pharma Mar 24

TTY Biopharm Enters into Licensing Agreement with PharmaMar 25

PharmaMar Enters into Licensing Agreement with Chugai Pharma for Aplidin 26

PharmaMar Enters into Licensing Agreement with GP Pharm for Politrate Leuprorelin 27

Equity Offering 28

Pharma Mar Plans to Raise Funds through Public Offering of ADS 28

Pharma Mar SA-Key Competitors 29

Pharma Mar SA-Key Employees 30

Pharma Mar SA-Locations And Subsidiaries 31

Head Office 31

Other Locations & Subsidiaries 31

Recent Developments 33

Financial Announcements 33

Oct 30, 2018: PharmaMar reports net profit of EUR5 million at the end of the third quarter of 2018 33

Jul 26, 2018: PharmaMar group obtained a net profit of EUR3 million in the first half of 2018 34

Apr 26, 2018: Pharmamar Group Reports First Quarter Financial Results 35

Feb 28, 2018: PharmaMar group announces 2017 earnings results 36

Oct 24, 2017: Pharma Mar group revenues totalled EUR140 million in the first nine months of the year 37

Jul 26, 2017: Pharma Mar group reports first half financial results 38

Apr 27, 2017: PharmaMar Group reports EUR45.5 million in revenues (+8%) 39

Feb 24, 2017: PharmaMar continues to execute commercially in 2016, adds new partner for pipeline asset, and sees pipeline progress 40

Corporate Communications 42

Oct 01, 2018: PharmaMar names Ali Zeaiter as new Director of Clinical Development 42

Government and Public Interest 43

Mar 29, 2017: The success of sarcoma treatment, seen by prestigious international oncologists 43

Product News 45

06/16/2017: PharmaMar Will Commercialize PM1183 With the Trade Name of Zepsyre 45

04/27/2017: PharmaMar demonstrates its progress in R&D in New York 46

04/04/2017: PharmaMar Presents New Data on Lurbinectedin at the AACR Congress 47

Clinical Trials 48

Sep 19, 2017: PharmaMar Starts Clinical Studies with a New Compound -PM14- in Patients with Solid Tumors 48

Jun 13, 2017: PharmaMar Announces Encouraging Results in Clinical Trials of Lurbinectedin in Endometrial and Breast Cancers 49

May 18, 2017: PharmaMar Announces new data on Lurbinectedin during ASCO 2017 50

Other Significant Developments 51

Jul 30, 2018: Immedica-a platform for pan-European niche specialty pharma launch, commercialization and distribution services 51

Jun 28, 2018: PharmaMar's 2017 Group Annual General Shareholder's' meeting 52

Jun 29, 2017: PharmaMar Group reviews 2016 at its annual general shareholders meeting 54

Appendix 55

Methodology 55

About GlobalData 55

Contact Us 55

Disclaimer 55


List Of Figure

List of Figures

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Pharma Mar SA, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Pharma Mar SA, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Pharma Mar SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Pharma Mar SA, Deals By Therapy Area, 2012 to YTD 2018 9

Pharma Mar SA, Medical Devices Deals, 2012 to YTD 2018 10

Pharma Mar SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Pharma Mar Enters into Distribution Agreement with Impilo Pharma 12

Pharma Mar Enters into Agreement with Spanish National Cancer Research Centre 13

Zeltia Merges with Pharma Mar in Reverse Merger Transaction 14

Pint Pharma International Enters into Licensing Agreement with Pharma Mar 15

Seattle Genetics Enters into Licensing Agreement with Pharma Mar 16

Pharma Mar Enters into Licensing Agreement with Megapharm 17

Pharma Mar to Enter into Licensing Agreement with Boryung Pharma 18

Boryung Pharm Enters into Licensing Agreement with Pharma Mar 19

Eczacibasi Enters into Licensing Agreement with Pharma Mar 20

Specialised Therapeutics Asia Enters into Licensing Agreement with Pharma Mar 21

Boryung Pharma Enters into Licensing Agreement with Pharma Mar 22

Specialised Therapeutics Enters into Licensing Agreement with Pharma Mar 23

Specialised Therapeutics Enters into Licensing Agreement with Pharma Mar 24

TTY Biopharm Enters into Licensing Agreement with PharmaMar 25

PharmaMar Enters into Licensing Agreement with Chugai Pharma for Aplidin 26

PharmaMar Enters into Licensing Agreement with GP Pharm for Politrate Leuprorelin 27

Pharma Mar Plans to Raise Funds through Public Offering of ADS 28

Pharma Mar SA, Key Competitors 29

Pharma Mar SA, Key Employees 30

Pharma Mar SA, Subsidiaries 31

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Pharma Mar SA, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.